bleximenib oxalate

Bleximenib oxalate (Menin-MLL inhibitor 24 oxalate) is a selective and highly efficient menin-MLL inhibitor. It shows antiproliferative activity in acute lymphoblastic leukemia (ALL) cell lines and inhibits the binding of the menin-KMT2A complex to chromatin at the target gene promoter.

Bleximenib (JNJ-75276617) oxalate is an orally active and highly selective menin–KMT2A interaction inhibitor, with IC50 values of 0.1 nM in humans, 0.045 nM in mice, and ≤0.066 nM in dogs, Bleximenib effectively suppresses tumor cell proliferation while inducing apoptosis and cellular differentiation. Bleximenib serves as a powerful investigational agent for leukemia and other KMT2A-driven malignancies in preclinical cancer research.